| Name | Omarigliptin |
| Description | Omarigliptin is a potent and selective oral dipeptidyl peptidase 4 (DPP4) inhibitor with IC50 value of 1.6 nM. [3] |
| In vitro | METHODS: HrGECs cells were stimulated with 0, 1, 2, 10, 20, 100 and 200 μM Omarigliptin for 24 hours and cell viability was observed.
RESULTS When the concentration of Omarigliptin was 100 and 200 μM, the viability of HrGECs cells decreased significantly. [2] |
| In vivo | METHODS: A diabetic mouse model was established by treating with streptozotocin (STZ). Omarigliptin (2.5, 5 mg/kg, oral) was used to investigate the effects of Omarigliptin on glucose and insulin levels, cognitive dysfunction, oxidative stress, SIRT3 and FOXO3a expression, and NAD/NADH activity in STZ-induced diabetic mice.
RESULTS Omarigliptin can significantly reduce blood glucose in STZ-induced diabetic mice, accompanied by increased serum insulin levels; Omarigliptin improves cognitive dysfunction in STZ-induced diabetic mice; Omarigliptin treatment rescues GSH in the hippocampus in a dose-dependent manner; Omarigliptin induces increased SIRT3 expression and prevents FOXO3a acetylation. [1] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 50 mg/mL (125.49 mM)
|
| Keywords | Omarigliptin | inhibit | glucagon like peptide-1 | anti-parkinsonian | Dipeptidyl Peptidase | blood-brain barrier | MK 3102 | DPP | orally active | Inhibitor | MK3102 | anti-diabetic |
| Inhibitors Related | Sitagliptin | Sitagliptin phosphate monohydrate | Linagliptin | Vildagliptin | Alloxan monohydrate | 4'-Hydroxychalcone |
| Related Compound Libraries | Highly Selective Inhibitor Library | Glycometabolism Compound Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Drug Repurposing Compound Library | Neuroprotective Compound Library | Inhibitor Library | NO PAINS Compound Library | Clinical Compound Library | Bioactive Compounds Library Max |
United States
